Outcomes of Tolerating Subretinal Fluid in Type 1 MNV and PCV

Sponsor
Kim's Eye Hospital
Study ID
NCT05662943
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
50 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

The purpose of the present study was to evaluate the outcomes of type 1 macular neovascularization (MNV), including polypoidal choroidal vasculopathy in patients treated tolerating subretinal fluid (SRF) using Aflibercept in a clinical setting. Approximately 150 patients are anticipated to be enrolled in this study. SRF is a primary type of fluid compartment prevalent in type 1 aneurysmal MNV. In a recent study, the prevalence of SRF during 24-month follow-up period was 36.7% to 38.8% in type 1 MNV and polypoidal choroidal vasculopathy (PCV), 20.0% in type 2 MNV, and 7.7% in type 3 MNV. In addition, patients with SRF showed better visual prognosis in type 1 MNV/PCV. For this reason, type 1 MNV is an appropriate candidate for evaluating the influence of tolerating SRF.

Key Dates

Start date
Dec 5, 2022
Status verified
Dec 2022
Primary completion
May 31, 2023
Completion
Nov 30, 2023

Study Design

Enrollment
135 participants (actual)

Arms

  • Arm: Type 1 Macular Neovascularization and Polypoidal Choroidal Vasculopathy
    Patients with type 1 macular neovascularization and polypoidal choroidal vasculopathy who underwent continuous aflibercept injections with tolerating subfoveal retinal fluid more than 6 months

Primary Outcome Measure

Changes in visual acuity [ Time Frame: Through study completion, an average of 20 months ]

Related Studies